-
Regulatory approvals for Covaxin are in process in more than 60 countries including USA, Brazil and Hungary, says the Hyderabad company.
-
The daily vaccination rate has fallen to 1.3 million doses despite India not exporting the vaccines now
-
Experts say it can turn into an endemic that causes cold during winter when conditions are favourable for its transmission
-
Chief Minister Pramod Sawant said only 60 per cent of this segment had been covered in the vaccination drive.
-
Sputnik V was registered in India under the emergency use authorization procedure on April 12, and vaccination against coronavirus with the Russian vaccine started on May 14.
-
A total of 19,60,51,962 vaccine doses have been administered through 28,16,725 sessions, according to the provisional report till 7 am.
-
As most of them do not own smartphones, the registration is being done offline
-
Company plans to produce an additional 200 million doses of Covaxin per annum in the GMP facilities located at Ankleshwar, Gujarat, starting from the fourth quarter of 2021
-
In a letter to CM KCR, the Union Minister of State said railway staff was rendering various services round-the-clock during the pandemic and urged to vaccinate the staff on priority basis
-
The package includes air tickets from Delhi to Moscow, 24-day stay in Russia, two doses of Sputnik V, 24 breakfast and Indian dinner all at a cost of Rs1.29 lakh per person.
-
As there were a few technical glitches pertaining to vaccine registration, a plan is being tabled to make sure the second jab is given at the same vaccination centre where the first dose was administered, said the Minister
-
The Centre has so far provided over 20 crore (20,76,10,230) vaccine doses to the states and Union territories for free.
-
Pilot programme to administer from the first batch of 1,50,000 doses of Sputnik V vaccines imported from RDIF
-
The discussions are currently ongoing with Bharat Biotech towards reviewing the infrastructure at Hester, the technology adaption process and the regulatory compliances.
-
The decision-making process gets dominated by personal risk concerns. The best way to counter those concerns, therefore, is to highlight the opposite: personal benefits
-
Factors such as vaccine hesitancy and mistaken beliefs about the risks COVID-19 poses to children may make this a challenging goal.
-
The imported doses of the vaccine are presently priced at Rs 995 (Rs 948 plus 5 per cent GST per dose), with the possibility of a lower price point when local supply begins.
-
Terms data as strategic ammunition available for managing the pandemic
-
States like Telangana opting for global tenders to procure vaccine is a pragmatic decision, given the Centre's opaque policy
-
On Tuesday, Health Minister Rajesh Tope had alleged that the Union government was not fulfilling its responsibility to provide adequate number of vaccine doses to states.
